Literature DB >> 20410257

PD-1 deficiency results in the development of fatal myocarditis in MRL mice.

Jian Wang1, Il-Mi Okazaki, Taku Yoshida, Shunsuke Chikuma, Yu Kato, Fumio Nakaki, Hiroshi Hiai, Tasuku Honjo, Taku Okazaki.   

Abstract

The deficiency of programmed cell death 1 (PD-1, Pdcd1), a negative immuno-receptor belonging to the CD28/cytotoxic T lymphocyte antigen 4 (CTLA-4) family, can support various tissue-specific autoimmune conditions. Here, we analyzed the effect of PD-1 deficiency in MRL mice that is genetically predisposed to systemic autoimmunity. MRL-Pdcd1(-)(/-) mice developed a fatal myocarditis, which is reminiscent of CTLA-4-deficient (Ctla4(-)(/-)) mice. Massive infiltration of CD4(+) and CD8(+) T cells and myeloid cells was found in hearts of MRL-Pdcd1(-)(/-) mice concomitant with the production of high-titer auto-antibodies against cardiac myosin. In contrast to Ctla4(-)(/-) mice in which most of the CD4(+) T cells are non-specifically activated and invade various organs, T cells in the heart but not in the spleen and lymph nodes are activated in MRL-Pdcd1(-)(/-) mice, suggesting that myocarditis is mediated by antigen-specific autoimmune response. Heart infiltrating myeloid cells strongly suppressed the allogenic response of T cells in vitro, suggesting that these Mac1(+)Gr1(+) myeloid cells are phenotypically similar to myeloid suppressor cells, which can be found in tumor-bearing hosts. These findings unravel the hidden heart-specific autoimmune predisposition of MRL mice and provide MRL-Pdcd1(-)(/-) mice as a useful animal model of lymphocytic myocarditis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410257     DOI: 10.1093/intimm/dxq026

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  84 in total

1.  Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.

Authors:  James Randall Patrinely; Arissa C Young; Henry Quach; Grant R Williams; Fei Ye; Run Fan; Leora Horn; Kathryn E Beckermann; Erin A Gillaspie; Jeffrey A Sosman; Debra L Friedman; Javid J Moslehi; Douglas B Johnson
Journal:  Eur J Cancer       Date:  2020-06-27       Impact factor: 9.162

Review 2.  A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.

Authors:  Taku Okazaki; Shunsuke Chikuma; Yoshiko Iwai; Sidonia Fagarasan; Tasuku Honjo
Journal:  Nat Immunol       Date:  2013-12       Impact factor: 25.606

Review 3.  Cardiotoxicity of Immune Checkpoint Inhibitors.

Authors:  Lili Zhang; Maeve Jones-O'Connor; Magid Awadalla; Daniel A Zlotoff; Paaladinesh Thavendiranathan; John D Groarke; Alexandra-Chloe Villani; Alexander R Lyon; Tomas G Neilan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-06-08

Review 4.  [Novel cancer treatment and the cardiovascular risk : What should cardiologists know?]

Authors:  Matthias Totzeck; Tienush Rassaf
Journal:  Herz       Date:  2020-04       Impact factor: 1.443

Review 5.  Cardiac Autoimmunity: Myocarditis.

Authors:  William Bracamonte-Baran; Daniela Čiháková
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 6.  Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.

Authors:  Nicholas Borcherding; Ryan Kolb; Jodi Gullicksrud; Praveen Vikas; Yuwen Zhu; Weizhou Zhang
Journal:  J Mol Biol       Date:  2018-05-22       Impact factor: 5.469

7.  PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.

Authors:  Kathryn W Juchem; Faruk Sacirbegovic; Cuiling Zhang; Arlene H Sharpe; Kerry Russell; Jennifer M McNiff; Anthony J Demetris; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

8.  Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response.

Authors:  Yuxiang Rui; Tasuku Honjo; Shunsuke Chikuma
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

Review 9.  Cardio-toxicity of checkpoint inhibitors.

Authors:  Oliver J Müller; Martina E Spehlmann; Norbert Frey
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

10.  Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.

Authors:  Robert Gibson; Jess Delaune; Anita Szady; Merry Markham
Journal:  BMJ Case Rep       Date:  2016-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.